BioXcel Therapeutics Inc (NASDAQ:BTAI) Stock Holdings Decreased by Moody Aldrich Partners LLC

Moody Aldrich Partners LLC reduced its position in BioXcel Therapeutics Inc (NASDAQ:BTAI) by 75.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,377 shares of the company’s stock after selling 60,265 shares during the period. Moody Aldrich Partners LLC owned about 0.10% of BioXcel Therapeutics worth $1,027,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. UBS Group AG boosted its holdings in shares of BioXcel Therapeutics by 16.5% during the fourth quarter. UBS Group AG now owns 93,084 shares of the company’s stock worth $1,360,000 after purchasing an additional 13,182 shares during the period. Geode Capital Management LLC boosted its holdings in shares of BioXcel Therapeutics by 27.9% during the fourth quarter. Geode Capital Management LLC now owns 79,204 shares of the company’s stock worth $1,157,000 after purchasing an additional 17,295 shares during the period. Strs Ohio boosted its holdings in shares of BioXcel Therapeutics by 48.2% during the first quarter. Strs Ohio now owns 12,600 shares of the company’s stock worth $281,000 after purchasing an additional 4,100 shares during the period. Capital Investment Advisory Services LLC acquired a new stake in shares of BioXcel Therapeutics during the first quarter worth approximately $320,000. Finally, HighPoint Advisor Group LLC acquired a new stake in shares of BioXcel Therapeutics during the first quarter worth approximately $236,000. 29.71% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms have issued reports on BTAI. BMO Capital Markets lifted their target price on shares of BioXcel Therapeutics from $64.00 to $104.00 and gave the company a “positive” rating in a research note on Monday, July 20th. BidaskClub upgraded shares of BioXcel Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 25th. Canaccord Genuity lifted their target price on shares of BioXcel Therapeutics from $71.00 to $120.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Guggenheim began coverage on shares of BioXcel Therapeutics in a research note on Thursday, June 4th. They issued a “buy” rating and a $101.00 target price for the company. Finally, Bank of America lifted their target price on shares of BioXcel Therapeutics from $53.00 to $63.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $102.00.

BTAI stock traded down $3.11 on Friday, reaching $45.36. 1,300,600 shares of the company were exchanged, compared to its average volume of 794,181. BioXcel Therapeutics Inc has a 12 month low of $3.76 and a 12 month high of $71.50. The stock’s fifty day moving average price is $53.66 and its 200 day moving average price is $35.81. The company has a current ratio of 6.82, a quick ratio of 6.82 and a debt-to-equity ratio of 0.01.

BioXcel Therapeutics (NASDAQ:BTAI) last announced its earnings results on Tuesday, May 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.21). As a group, sell-side analysts predict that BioXcel Therapeutics Inc will post -2.96 EPS for the current year.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.

Read More: What Is An Exchange-Traded Fund (ETF)?

Want to see what other hedge funds are holding BTAI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioXcel Therapeutics Inc (NASDAQ:BTAI).

Institutional Ownership by Quarter for BioXcel Therapeutics (NASDAQ:BTAI)

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.